Archemix and Dicerna will collaborate on R&D
Two local life sciences companies said they are teaming up to collaborate on some research-and-development work.
The companies are Archemix Corp., a Cambridge company focused on commercializing aptamer therapeutics, and Dicerna Pharmaceuticals Inc., a Watertown firm seeking to use RNAi gene-silencing technologies to develop novel drug treatments
In a press release, the companies said that they have entered into an agreement to collaborate on aptamer-DsiRNA therapeutics that leverage both the intracellular delivery capabilities of Archemix's aptamers and the gene silencing of Dicerna's DsiRNA molecules.
"The agreement includes an option for Dicerna to obtain exclusive rights to further develop and commercialize aptamer-DsiRNA therapeutics generated during the collaboration," the press release said. "Additional terms of the agreement were not disclosed."